We use cookies for a better user experience. Read our Privacy Policy

I Agree

Focal Segmental Glomerulosclerosis (FSGS) Market

Focal Segmental Glomerulosclerosis (FSGS) Market (Disease Type - Primary Focal Segmental Glomerulosclerosis and Secondary Focal Segmental Glomerulosclerosis; Disease Management - Diagnosis (Kidney Biopsy and Creatine Test) and Treatment (Drug Therapy, Dialysis, and Kidney Transplant) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025

Global Focal segmental glomerulosclerosis (FSGS) Market: Snapshot

Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on rare diseases too are proving beneficial for the market for focal segmental glomerulosclerosis.

Rising at a 8.0% CAGR from 2017 to 2025, the global focal segmental glomerulosclerosis (FSGS) market will likely become worth US$15.83 bn by 2025-end fromUS$7.82 bn in 2016, finds a report by Transparency Market Research.

focal segmental glomerulosclerosis market

Primary Focal Segmental Glomerulosclerosis Garners Greater Market Share due to Awareness About it

Depending upon the disease type, the market can be bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Of the two, the segment of primary focal segmental glomerulosclerosis held a mammoth 79.8% share in the market in 2016. Also known as primary idiopathic/genetic focal segmental glomerulosclerosis, primary focal segmental glomerulosclerosis is a kind of the focal segmental glomerulosclerosis disease without a known or obvious cause. Growing awareness about the disease and its management is at the forefront of driving growth in the segment.

Depending upon the management of the disease, the global market for focal segmental glomerulosclerosis (FSGS) can again be split broadly into diagnosis and treatment. The segment of diagnosis can be further divided into creatine test, kidney biopsy, etc. The segment of treatment again can be further divided into drug therapy, kidney transplant, and dialysis. At present, the treatment segment contributes to most of the revenue in the market for focal segmental glomerulosclerosis (FSGS). This is because of the massive unmet requirements in the market. A promising pipeline of novel molecules and their approval will continue boosting the segment in the next couple of years.

Considerable Penetration of Treatment Drives U.S. Market to Fore

Geographically, North America accounts for a leading share in the market for focal segmental glomerulosclerosis because of the presence of a properly structured health care industry and availability of reimbursement policies with wider coverage. The U.S. is mainly serving to drive the market in North America due to the greater uptake of advanced and high-cost drug therapies, considerable penetration of treatment, and helpful reimbursement policies. Another factor stoking market growth in the U.S. is the classification of focal segmental glomerulosclerosis (FSGS) drugs under orphan disease drugs categories – companies involved in the production and clinical trials of drugs for orphan diseases receive exemption from payment of new drug application fee, provision of tax credits on clinical research, waivers for post-approval annual establishment and product fees, and exclusive marketing rights up to a period of seven years.

Europe trails North America in terms of market share. In 2016, the segment accounted for a share of 25.5%. Vis-à-vis growth rate, Asia Pacific is expected to outshine all other regions. The market in the region is being powered primarily by China which in turn is being propelled by the increasing diagnosis rate of focal segmental glomerulosclerosis, stupendous growth in the healthcare industry, and availability of drugs and dialysis at a lower price.

Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.

Participation of Interprofessional Team Improves Patient Care in Focal Segmental Glomerulosclerosis (FSGS) Market

Focal segmental glomerular sclerosis (FSGS) is associated with podocyte injury and is a major cause of nephrotic syndrome, affecting adults and children. It is most frequently associated with kidney diseases, including end-of-life disease. The prevalence of FSGS, relative to other glomerular disease diagnoses, is increasing. It has a high incidence of 7 per 1 million with a prevalence as high as 4.0% according to some estimates. Advances made in pathogenesis of focal segmental glomerular sclerosis (FSGS) have pointed its role in full-blown nephrotic syndrome in children, propelling the need for research in the focal segmental glomerular sclerosis (FSGS) market. Numerous etiologies drive focal segmental glomerulosclerosis (FSGS). Growing awareness about prevalence of kidney disease drive prospects in the FSGS market. Given the high morbidity in patient populations, notable advances made in genetic testing, lab testing, and kidney biopsies. New assessment approaches in renal histology are boosting focal segmental glomerulosclerosis (FSGS) market. Growing cases of end-stage renal disease (ESRD) attributed to FSGS in developed and emerging nations present alarming scenario. The role of interprofessional teams in improving patient care is thus increasing, and will open new vistas of growth for industry players in the market.

The massive severity of the Covid-19 pandemic and its subsequent outbreaks have led policy makers, regulators, and industry players, and even the common populace to come forward join hands and fight against the humanitarian crisis. The collaborations and engagements across the value chain have thus paved way to new healthcare models, business and operating models for the economy, and new ways of working. The still-emerging pandemic due to new variants of Sars-CoV-2 has recently created a panic in some parts of Asia. Nevertheless, global commitment to combat the mortality and morbidity has improved the scenario in recent weeks. The needs of the pandemic has also spurred the demand for new production of essential goods and industrial chemicals, thereby offering opportunities masked in challenges. These factors are also likely to shape the contours of the focal segmental glomerular sclerosis (FSGS) market.

The global focal segmental glomerulosclerosis (FSGS) market is segmented as follows:

Disease Type

  • Primary Focal Segmental Glomerulosclerosis
  • Secondary Focal Segmental Glomerulosclerosis

Disease Management

  • Diagnosis
    • Kidney Biopsy
    • Creatine Test
    • Others
  • Treatment
    • Drug Therapy
    • Dialysis
    • Kidney Transplant

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia & New Zealand
    • Rest of Asia
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
Focal Segmental Glomerulosclerosis (FSGS) Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of focal segmental glomerulosclerosis (FSGS) market?

The global focal segmental glomerulosclerosis (FSGS) market was worth US$7.82 bn and is projected to reach a value of US$15.83 bn by the end of 2025

What is the anticipated CAGR of the focal segmental glomerulosclerosis (FSGS) market in the forecast period?

Focal segmental glomerulosclerosis (FSGS) market is anticipated to grow at a CAGR of 8.0% during the forecast period

Which region is expected to project the highest market share in the global focal segmental glomerulosclerosis (FSGS) market?

North america accounted for a major share of the global focal segmental glomerulosclerosis (FSGS) market

What are the key driving factors for the growth of the focal segmental glomerulosclerosis (FSGS) market?

The U.S. is mainly serving to drive the focal segmental glomerulosclerosis (FSGS) market in North America due to the greater uptake of advanced and high-cost drug therapies, considerable penetration of treatment, and helpful reimbursement policies

Who are the key players in the global focal segmental glomerulosclerosis (FSGS) market?

Key players in the global focal segmental glomerulosclerosis (FSGS) market include Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions
     2.2. Research Methodology

3. Executive Summary
     3.1. Global Focal Segmental Glomerulosclerosis Market Snapshot

4. Market Overview
     4.1. Product Overview
     4.2. Key Industry Events
     4.3. Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, 2015–2025
     4.4. Market Opportunity Map
     4.5. Global Focal Segmental Glomerulosclerosis Market Outlook
     4.6. Overview of Clinical Trials
     4.7. Global Focal Segmental Glomerulosclerosis Prevalence Scenario-2016, by Region

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis 
     5.2. Drivers
            5.2.1. Increasing burden of focal segmental glomerulosclerosis (FSGS)
            5.2.2. Untapped market opportunities with a limited number of pipeline products
            5.2.3. Efforts by non-government organizations to raise awareness
            5.2.4. Strong focus on R&D activities for developing new therapies and drugs
            5.2.5. Rise in funding for research on rare diseases
     5.3. Restraints
            5.3.1. High cost of kidney dialysis and kidney transplant treatments
            5.3.2. Difficulty in recruitment for clinical trials
            5.3.3. Non-availability of approved drugs and dearth of trained medical professionals
     5.4. Opportunities
            5.4.1. Promising pipeline of novel molecules and their approval
            5.4.2. Unmet needs for management of focal segmental glomerulosclerosis (FSGS)

6. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
     6.1. Introduction 
     6.2. Key Findings
     6.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     6.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
            6.4.1. Primary Focal Segmental Glomerulosclerosis
            6.4.2. Secondary Focal Segmental Glomerulosclerosis
     6.5. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
     6.6. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type
     6.7. Key Trends

7. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Management
     7.1. Introduction 
     7.2. Key Findings
     7.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     7.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
            7.4.1. Diagnosis
            7.4.2. Treatment
     7.5. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
            7.5.1. Kidney Biopsy
            7.5.2. Creatine Test
            7.5.3. Others
     7.6. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
            7.6.1. Drug Therapy
            7.6.2. Dialysis
            7.6.3. Kidney Transplant
     7.7. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management 
     7.8. Key Trends

8. Global Focal Segmental Glomerulosclerosis Market Analysis, by Region
     8.1. Global Market Scenario, by Country
     8.2. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region 
     8.3. Global Focal Segmental Glomerulosclerosis Market Forecast, by Region
            8.3.1.  North America
            8.3.2. Europe
            8.3.3. Asia Pacific
            8.3.4. Latin America
            8.3.5. Middle East & Africa
     8.4. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region 
     8.5. Regulatory Scenario by Region/Key Countries

9. North America Focal Segmental Glomerulosclerosis Market Analysis
     9.1. Key Findings
     9.2. North America Focal Segmental Glomerulosclerosis Market Overview
     9.3. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     9.4. North America Focal Segmental Glomerulosclerosis Market Forecast, by Country
            9.4.1. U.S.
            9.4.2. Canada
     9.5. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     9.6. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     9.7. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     9.8. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     9.9. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
     9.10. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
     9.11. North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

10. Europe Focal Segmental Glomerulosclerosis Market Analysis
     10.1. Key Findings
     10.2. Europe Focal Segmental Glomerulosclerosis Market Overview
     10.3. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     10.4. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Country
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. Spain 
            10.4.4. France 
            10.4.5. Russia 
            10.4.6. Poland 
            10.4.7. Rest of Europe
     10.5. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     10.6. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     10.7. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     10.8. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     10.9. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     10.10. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     10.11. Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis
     11.1. Key Findings
     11.2. Asia Pacific Focal Segmental Glomerulosclerosis Market Overview
     11.3. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     11.4. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Country
            11.4.1. India 
            11.4.2. Japan 
            11.4.3. China 
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     11.6. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     11.7. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     11.8. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     11.9. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     11.10. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     11.11. Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

12. Latin America Focal Segmental Glomerulosclerosis Market Analysis
     12.1. Key Findings
     12.2. Latin America Focal Segmental Glomerulosclerosis Market Overview
     12.3. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     12.4. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Country
            12.4.1. Brazil
            12.4.2. Mexico 
            12.4.3. Rest of Latin America
     12.5. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     12.6. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     12.7. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     12.8. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     12.9. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     12.10. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     12.11. Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis
     13.1. Key Findings
     13.2. Middle East & Africa Focal Segmental Glomerulosclerosis Market Overview
     13.3. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
     13.4. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Country
            13.4.1. GCC Countries
            13.4.2. South Africa 
            13.4.3. Rest of Middle East & Africa
     13.5. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
     13.6. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
     13.7. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
     13.8. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
     13.9. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Diagnosis
     13.10. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management – Treatment
     13.11. Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis

14. Competition Landscape
     14.1. Competition Matrix 
     14.2. Company Profiles
            14.2.1. Variant Pharmaceuticals, Inc.
                      14.2.1.1. Company Details
                      14.2.1.2. Business Overview
                      14.2.1.3. Strategic Overview
                      14.2.1.4. SWOT Analysis
            14.2.2. ChemoCentryx, Inc. 
                      14.2.2.1. Company Details
                      14.2.2.2. Business Overview
                      14.2.2.3. Strategic Overview
                      14.2.2.4. SWOT Analysis
            14.2.3. Retrophin, Inc. 
                      14.2.3.1. Company Details
                      14.2.3.2. Business Overview
                      14.2.3.3. Strategic Overview
                      14.2.3.4. SWOT Analysis
            14.2.4. AbbVie, Inc.
                      14.2.4.1. Company Details
                      14.2.4.2. Business Overview
                      14.2.4.3. Financial Overview
                      14.2.4.4. Strategic Overview
                      14.2.4.5. SWOT Analysis
            14.2.5. Novartis AG 
                      14.2.5.1. Company Details
                      14.2.5.2. Business Overview
                      14.2.5.3. Financial Overview
                      14.2.5.4. Strategic Overview
                      14.2.5.5. SWOT Analysis
            14.2.6. Pfizer, Inc. 
                      14.2.6.1. Company Details
                      14.2.6.2. Business Overview
                      14.2.6.3. Financial Overview
                      14.2.6.4. Strategic Overview
                      14.2.6.5. SWOT Analysis
            14.2.7. AstraZeneca plc. 
                      14.2.7.1. Company Details
                      14.2.7.2. Business Overview
                      14.2.7.3. Financial Overview
                      14.2.7.4. Strategic Overview
                      14.2.7.5. SWOT Analysis
            14.2.8. Sanofi S.A.  
                      14.2.8.1. Company Details
                      14.2.8.2. Business Overview
                      14.2.8.3. Financial Overview
                      14.2.8.4. Strategic Overview
                      14.2.8.5. SWOT Analysis
            14.2.9. GlaxoSmithKline plc. 
                      14.2.9.1. Company Details
                      14.2.9.2. Business Overview
                      14.2.9.3. Financial Overview
                      14.2.9.4. Strategic Overview
                      14.2.9.5. SWOT Analysis
            14.2.10. Teva Pharmaceutical Industries Ltd. 
                      14.2.10.1. Company Details
                      14.2.10.2. Business Overview
                      14.2.10.3. Financial Overview
                      14.2.10.4. Strategic Overview
                      14.2.10.5. SWOT Analysis

List of Tables

TABLE 1 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 2 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 3 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 4 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 5 Global Focal Segmental Glomerulosclerosis Market Revenue (US$ Mn) Forecast, by Region, 2015–2025
TABLE 6 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country, 2015–2025
TABLE 7 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 8 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 9 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease
TABLE 10 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 11 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 12 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 13 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management,
TABLE 14 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 15 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 16 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 17 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 18 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 19 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 20 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 21 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 22 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 23 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 24 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 25 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025
TABLE 26 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 27 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
TABLE 28 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management, 2015–2025
TABLE 29 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Diagnosis, 2015–2025
TABLE 30 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, by Disease Management - Treatment, 2015–2025

List of Figures

FIG. 1 Market Opportunity Map - By Disease Type, 2016 Revenue Share
FIG. 2 Market Opportunity Map - By Disease Management, 2016 Revenue Share
FIG. 3 Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, 2015–2025
FIG. 4 Market Value Share, by Disease Management - Diagnosis (2016)
FIG. 5 Market Value Share, by Disease Management - Treatment (2016)
FIG. 6 Market Value Share, by Disease Type (2016)
FIG. 7 Market Value Share, by Region (2016)
FIG. 8 Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 9 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Primary Focal Segmental Glomerulosclerosis, 2015–2025
FIG. 10 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Secondary Focal Segmental Glomerulosclerosis, 2015–2025
FIG. 11 Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 12 Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 13 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) and Y-o-Y Growth, by Diagnosis, 2015–2025
FIG. 14 Global Focal Segmental Glomerulosclerosis Market Value (US$ Mn) and Y-o-Y Growth, by Treatment, 2015–2025
FIG. 15 Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 16 Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region, 2016 and 2025
FIG. 17 Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region, 2017–2025 
FIG. 18 North America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 19 North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country, 2017–2025
FIG. 20 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country, 2016 and 2025
FIG. 21 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 22 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 23 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 24 North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 25 North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 26 North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 27 Europe Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 28 Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 29 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 30 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 31 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 32 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 33 Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 34 Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 35 Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 36 Asia Pacific Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 37 Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 38 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 39 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 40 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 41 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 42 Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 43 Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 44 Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 45 Latin America Focal Segmental Glomerulosclerosis Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
FIG. 46 Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 47 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 48 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 49 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 50 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 51 Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 52 Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type, 2015–2025
FIG. 53 Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management, 2015–2025
FIG. 54 Middle East & Africa Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
FIG. 55 Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
FIG. 56 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
FIG. 57 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type, 2016 and 2025
FIG. 58 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management, 2016 and 2025
FIG. 59 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Diagnosis, 2016 and 2025
FIG. 60 Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management - Treatment, 2016 and 2025
FIG. 61 AbbVie, Inc. - Breakdown of Net Sales, by Region,2015
FIG. 62 AbbVie, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 63 Novartis AG Breakdown of Net Sales, by Region, 2016
FIG. 64 Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
FIG. 65 Pfizer, Inc. Breakdown of Net Sales, by Region, 2015
FIG. 66 Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 67 AstraZeneca plc Breakdown of Net Sales, by Region, 2015
FIG. 68 AstraZeneca plc Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 69 Sanofi S.A. Breakdown of Net Sales, by Region, 2015
FIG. 70 Sanofi S.A. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 71 GlaxoSmithKline plc. Breakdown of Net Sales, by Region,2015
FIG. 72 GlaxoSmithKline plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015
FIG. 73 Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region, 2015
FIG. 74 Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

906

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved